Phase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC Meeting Abstract
| Authors: | Planchard, D.; Janne, P. A.; Yu, H. A.; Moro-Sibilot, D.; Goldberg, T.; Gu, X.; Li, J.; McGill, J.; Yu, C.; Slosberg, E. |
| Abstract Title: | Phase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC |
| Meeting Title: | 43rd ESMO Congress (ESMO 2018) |
| Journal Title: | Annals of Oncology |
| Volume: | 29 |
| Issue: | Suppl. 8 |
| Meeting Dates: | 2018 Oct 19-23 |
| Meeting Location: | Munich, Germany |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-10-01 |
| Start Page: | mdy292.127 |
| Language: | English |
| ACCESSION: | WOS:000459277303276 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdy292.127 |
| Notes: | Meeting Abstract: 1506TiP -- Appears on pages viii545-viii546 of the abstract book -- Source: Wos |
